StreetInsider.com News Articles

TransCode Therapeutics to present TTX-MC138 trial data at ESMO 2026

Mon, 19 Oct 2026 08:04:09 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced that a poster presenting Phase 1a clinical trial data for its lead drug candidate, TTX-MC138, has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on October 23, 2026.

The poster, titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors," will present clinical data from the Phase 1a evaluation of TTX-MC138 in patients with advanced solid tumors. TTX-MC138 is an investigational drug designed to target miR-10b, a microRNA associated with metastatic disease progression.

The presentation is listed under the Developmental Therapeutics category as

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

Mon, 19 Oct 2026 08:04:00 -0400

Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors

BOSTON, Oct. 19, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced that a poster featuring TTX-MC138, the Company's lead therapeutic candidate, has

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

Mon, 19 Oct 2026 08:04:00 -0400

Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors

Natera and TransCode team up on colorectal cancer MRD trial

Tue, 13 Oct 2026 07:30:21 -0400

Natera, Inc. (Nasdaq: NTRA) and TransCode Therapeutics, Inc. (Nasdaq: RNAZ) have announced a collaboration to support patient enrollment in TransCode's Phase 2a clinical trial evaluating TTX-MC138 in colorectal cancer (CRC).

Under the agreement, Natera's Signatera test will be used to identify patients who have completed curative-intent therapy and test positive for molecular residual disease (MRD) with no radiographic evidence of disease. Those patients would be eligible for enrollment in the trial.

TTX-MC138 is designed to inhibit microRNA-10b (miR-10b), a biomarker linked to the emergence and progression of metastatic cancers, including CRC. TransCode describes the candidate as a first-in-class therapeutic targeting MRD-positive patients

Natera and TransCode team up on colorectal cancer MRD trial

Tue, 13 Oct 2026 07:30:21 -0400

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC).

The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-MC138 in patients with CRC. Patients will be eligible for enrollment if they have completed curative-intent therapy and

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Form 8-K Transcode Therapeutics, For: Oct 01

Thu, 01 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261001/27135899.html

Form 8-K Transcode Therapeutics, For: Sep 28

Mon, 28 Sep 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260928/27110480.html

TransCode reports Phase 1a trial data for TTX-MC138 in solid tumors

Mon, 28 Sep 2026 08:04:20 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) released updated clinical data from its Phase 1a trial of TTX-MC138, an anti-miR-10b therapeutic candidate, in patients with relapsed, refractory, or metastatic solid tumors, according to a company statement dated Sept. 28, 2026.

As of the Sept. 1, 2026, data cutoff, 10 of 14 efficacy-evaluable patients, or 71.4%, achieved stable disease as their best overall response. The disease control rate was 57.1% at three months and 35.7% at six months. Three of 14 patients remained progression-free at both nine and 12 months. A total of 98 doses have been administered across the study.

The trial met its

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

Mon, 28 Sep 2026 08:04:00 -0400

Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors

In the 14 efficacy-evaluable patients:
- 71.4% stable disease rate
- 57.1% of patients had disease control through three months of therapy
- 36.7% maintained disease control through six months of therapy
- Three efficacy-evaluable patients remain progression-free at

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

Mon, 28 Sep 2026 08:04:00 -0400

Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors

In the 14 efficacy-evaluable patients:
- 71.4% stable disease rate
- 57.1% of patients had disease control through three months of therapy
- 36.7% maintained disease control through six months of therapy
- Three efficacy-evaluable patients remain progression-free at

TransCode Therapeutics receives patent approvals in Australia and Japan

Tue, 22 Sep 2026 08:04:57 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced that it has received patent approvals in Australia and Japan for technologies related to its RNA-based cancer therapy platform, according to a press release issued Sept. 22, 2026.

IP Australia issued a Notice of Acceptance for Patent Application No. 2019349817, titled "Compositions and Methods for Immune Checkpoint Inhibition." The application covers nanoparticle compositions that deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims include nanoparticles with an iron oxide core, a dextran polymer coating, and a covalently linked siRNA, with methods of use across colon, lung, breast, pancreatic, and ovarian cancers. The

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

Tue, 22 Sep 2026 08:04:00 -0400

Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation

BOSTON, Sept. 22, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

Tue, 22 Sep 2026 08:04:00 -0400

Allowances of Patent Applications in Australia and Japan support differentiated RNA platform for targeted cancer therapy and immune modulation

Form 3 Transcode Therapeutics, For: Sep 10 Filed by: Tattory John A

Mon, 21 Sep 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260921/27086176.html

Join Today's Live Investor Webinar with TransCode Therapeutics

Wed, 16 Sep 2026 09:00:00 -0400

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancers

Management to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalysts

ORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p.m. ET with TransCode Therapeutics, Inc. (NASDAQ:RNAZ). The webinar is free to attend and open to all.

The exclusive event will feature Philippe P. Calais Ph.D., Chairman and CEO; Zdravka Medarova, Ph.D.,

Join Today's Live Investor Webinar with TransCode Therapeutics

Wed, 16 Sep 2026 09:00:00 -0400

Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancers

Management to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalysts

The exclusive event will feature Philippe P. Calais Ph.D., Chairman and CEO; Zdravka Medarova, Ph.D.,

Form 4 Transcode Therapeutics, For: Sep 09 Filed by: Fitzgerald Thomas A

Fri, 11 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27053637.html

Form 8-K Transcode Therapeutics, For: Sep 09

Fri, 11 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260911/27053564.html

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Fitzgerald has served as CFO since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program for lead product candidate TTX-MC138, and the acquisition of Polynoma and a license agreement with Oncolytics.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key